Pelvic spindle cell sarcomas harboring MEIS1::NCOA2 fusion and novel gene amplifications in 10q23-26 region: a potential predictor for tumor progression.
{"title":"Pelvic spindle cell sarcomas harboring MEIS1::NCOA2 fusion and novel gene amplifications in 10q23-26 region: a potential predictor for tumor progression.","authors":"Yu Gao, Yang Lu, Jian Cui, Xin He, Hongying Zhang","doi":"10.1007/s00428-025-04079-5","DOIUrl":null,"url":null,"abstract":"<p><p>MEIS1::NCOA1/2 fusion undifferentiated spindle cell sarcomas generally arise from genitourinary and gynecologic tracts and mostly exhibit low-grade malignancies according to limited cases. Here, we report two cases from pelvic cavities. Case 1 showed low-grade morphology of monotonous spindle cells with moderate atypia in short fascicular or storiform patterns, while case 2 exhibited marked atypia, brisk mitosis, and significant necrosis. Notably, both cases identified intracytoplasmic eosinophilic globules. Next-generation sequencing analysis observed MEIS1::NCOA2 rearrangements in both cases, but only case 2 detected additional 10q23-26 amplifications and CTNNB1 mutation (c.94G > T/p.D32Y). Case 1 developed twice local recurrences in 3 years, while case 2 metastasized to the liver and gastroduodenal interstice and died 7 months after intraabdominal surgery. To the best of our knowledge, it is the first report about MEIS1::NCOA2 fusion sarcoma with distant metastasis to the abdomen. The extra 10q23-26 amplifications and CTNNB1 mutation may indicate potential predictors for malignancy in this study.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04079-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
MEIS1::NCOA1/2 fusion undifferentiated spindle cell sarcomas generally arise from genitourinary and gynecologic tracts and mostly exhibit low-grade malignancies according to limited cases. Here, we report two cases from pelvic cavities. Case 1 showed low-grade morphology of monotonous spindle cells with moderate atypia in short fascicular or storiform patterns, while case 2 exhibited marked atypia, brisk mitosis, and significant necrosis. Notably, both cases identified intracytoplasmic eosinophilic globules. Next-generation sequencing analysis observed MEIS1::NCOA2 rearrangements in both cases, but only case 2 detected additional 10q23-26 amplifications and CTNNB1 mutation (c.94G > T/p.D32Y). Case 1 developed twice local recurrences in 3 years, while case 2 metastasized to the liver and gastroduodenal interstice and died 7 months after intraabdominal surgery. To the best of our knowledge, it is the first report about MEIS1::NCOA2 fusion sarcoma with distant metastasis to the abdomen. The extra 10q23-26 amplifications and CTNNB1 mutation may indicate potential predictors for malignancy in this study.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.